South African Hypertension Guideline 2006

dc.contributor.authorSeedat, Y K
dc.contributor.authorCroasdale, M A
dc.contributor.authorMilne, F J
dc.contributor.authorOpie, L H
dc.contributor.authorPinkney-Atkinson, VJ
dc.contributor.authorRayner, B L
dc.contributor.authorVeriava Y
dc.date.accessioned2017-07-06T08:30:40Z
dc.date.available2017-07-06T08:30:40Z
dc.date.issued2006
dc.date.updated2016-01-12T08:52:17Z
dc.description.abstractOutcomes. Extensive data from many randomised controlled trials have shown the benefit of treating hypertension. The target blood pressure (BP) for antihypertensive management should be systolic BP < 140 mmHg, diastolic BP < 90 mmHg, with minimal or no drug side-effects. However, a lesser reduction will elicit benefit although this is not optimal. The reduction of BP in the elderly should generally be achieved gradually over 6 months. Stricter BP control is required for patients with end-organ damage, co-existing risk factors and co-morbidity, e.g. diabetes mellitus. Co-existent risk factors should also be controlled. Benefits. Reduction in risk of stroke, cardiac failure, renal insufficiency and coronary artery disease. The major precautions and contraindications to each antihypertensive drug recommended are listed. Recommendations. Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. The total cardiovascular disease risk profile should be determined for all patients and this should inform management strategies. Lifestyle modification and patient education are cornerstones in the management of every patient. Drug therapy for the patient with uncomplicated hypertension should be as follows: first line – low-dose thiazide or thiazide-like diuretics; second line – add either an angiotensin-converting enzyme inhibitor (ACE-I) or a calcium channel blocker (CCB); third line – add another second-line drug not already used. In resistant hypertension where a fourth drug is needed, use either a centrally acting drug, vasodilator, alpha-blocker, or beta-blocker. The order of drug choice may change in those with compelling indications for a particular drug class. The guideline includes management of specific situations including hypertensive emergency and urgency, severe hypertension with target-organ damage and hypertension in diabetes mellitus, etc. Validity. The guideline was developed by a joint Southern African Hypertension Society and National Department of Health Directorate: Chronic Diseases, Disabilities and Geriatrics working group. Input was also obtained from representatives of the various related professional societies.
dc.identifierhttp://dx.doi.org/10.7196/SAMJ.1111
dc.identifier.apacitationSeedat, Y. K., Croasdale, M. A., Milne, F. J., Opie, L. H., Pinkney-Atkinson, V., Rayner, B. L., & (2006). South African Hypertension Guideline 2006. <i>South African Medical Journal</i>, http://hdl.handle.net/11427/24701en_ZA
dc.identifier.chicagocitationSeedat, Y K, M A Croasdale, F J Milne, L H Opie, VJ Pinkney-Atkinson, B L Rayner, and "South African Hypertension Guideline 2006." <i>South African Medical Journal</i> (2006) http://hdl.handle.net/11427/24701en_ZA
dc.identifier.citationSeedat, Y.K., Croasdale, M.A., Milne, F.J., Opie, L.H., Pinkney-Atkinson, V.J., Rayner, B.L., & Veriava,Y. (2006). South African Hypertension Guidelines 2006. South African Medical Journal, 96(4), 335-362.
dc.identifier.ris TY - Journal Article AU - Seedat, Y K AU - Croasdale, M A AU - Milne, F J AU - Opie, L H AU - Pinkney-Atkinson, VJ AU - Rayner, B L AU - Veriava Y AB - Outcomes. Extensive data from many randomised controlled trials have shown the benefit of treating hypertension. The target blood pressure (BP) for antihypertensive management should be systolic BP < 140 mmHg, diastolic BP < 90 mmHg, with minimal or no drug side-effects. However, a lesser reduction will elicit benefit although this is not optimal. The reduction of BP in the elderly should generally be achieved gradually over 6 months. Stricter BP control is required for patients with end-organ damage, co-existing risk factors and co-morbidity, e.g. diabetes mellitus. Co-existent risk factors should also be controlled. Benefits. Reduction in risk of stroke, cardiac failure, renal insufficiency and coronary artery disease. The major precautions and contraindications to each antihypertensive drug recommended are listed. Recommendations. Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. The total cardiovascular disease risk profile should be determined for all patients and this should inform management strategies. Lifestyle modification and patient education are cornerstones in the management of every patient. Drug therapy for the patient with uncomplicated hypertension should be as follows: first line – low-dose thiazide or thiazide-like diuretics; second line – add either an angiotensin-converting enzyme inhibitor (ACE-I) or a calcium channel blocker (CCB); third line – add another second-line drug not already used. In resistant hypertension where a fourth drug is needed, use either a centrally acting drug, vasodilator, alpha-blocker, or beta-blocker. The order of drug choice may change in those with compelling indications for a particular drug class. The guideline includes management of specific situations including hypertensive emergency and urgency, severe hypertension with target-organ damage and hypertension in diabetes mellitus, etc. Validity. The guideline was developed by a joint Southern African Hypertension Society and National Department of Health Directorate: Chronic Diseases, Disabilities and Geriatrics working group. Input was also obtained from representatives of the various related professional societies. DA - 2006 DB - OpenUCT DP - University of Cape Town J1 - South African Medical Journal LK - https://open.uct.ac.za PB - University of Cape Town PY - 2006 T1 - South African Hypertension Guideline 2006 TI - South African Hypertension Guideline 2006 UR - http://hdl.handle.net/11427/24701 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/24701
dc.identifier.vancouvercitationSeedat YK, Croasdale MA, Milne FJ, Opie LH, Pinkney-Atkinson V, Rayner BL, et al. South African Hypertension Guideline 2006. South African Medical Journal. 2006; http://hdl.handle.net/11427/24701.en_ZA
dc.language.isoeng
dc.publisher.departmentDepartment of Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.sourceSouth African Medical Journal
dc.source.urihttp://www.samj.org.za/index.php/samj/index
dc.subject.otherSouth Africa
dc.subject.otherHypertension guidelines
dc.subject.otherDisease management
dc.subject.otherSouthern African Hypertension Society
dc.titleSouth African Hypertension Guideline 2006
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Seedat_SouthAfrican_Hypertension_2006.pdf
Size:
3.45 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Collections